Form 4: Teva Pharmaceutical Executive Christine Fox Executes Stock Sales to Cover Tax Obligations

EVP Christine Fox of Teva Pharmaceutical Industries sold shares to cover tax obligations related to vesting restricted share units, as per a pre-arranged Rule 10b5-1 trading plan.

Summary

• Christine Fox, EVP, Head of U.S. Commercial at Teva Pharmaceutical Industries, filed a Form 4 detailing changes in beneficial ownership.
• On March 4, 2025, Fox exercised 20,461 restricted share units, which converted into ordinary shares.
• Simultaneously, Fox disposed of 4,034 ordinary shares at a weighted average price of $15.7346 per share and 2,147 ordinary shares at a weighted average price of $15.9132 per share.
• These sales were executed to cover tax withholding obligations related to the vesting of the restricted share units.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on August 13, 2024.
• Following these transactions, Fox directly owns 58,384 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports stock transactions by an executive, which are part of normal compensation and tax planning. The existence of a 10b5-1 plan further reduces any potential negative sentiment.

Positives

• The transactions were pre-planned under a Rule 10b5-1 trading plan, indicating no insider information was used.

Future Outlook

The reporting person will continue to vest restricted share units on March 4 of 2026, 2027 and 2028.

Industry Context

Executive stock transactions are common and closely monitored, especially in the pharmaceutical industry, to ensure compliance with regulations and transparency for investors.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time, similar to those granted to Christine Fox.
• Rule 10b5-1 trading plans are a standard practice among corporate executives to avoid accusations of insider trading when selling company stock.
• Companies like Pfizer, Johnson & Johnson, and Merck also have executives who utilize similar trading plans to manage their stock holdings and tax obligations.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small volume and pre-planned nature of the transactions.

Key Dates

Keywords

Form 4, Teva Pharmaceutical Industries, Christine Fox, Beneficial Ownership, Stock Sale, Restricted Share Units, Rule 10b5-1, Tax Obligations